Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Acquisitions & Divestments (2018 - 2025)

Historic Change in Acquisitions & Divestments for Summit Therapeutics (SMMT) over the last 5 years, with Q2 2025 value amounting to $150.8 million.

  • Summit Therapeutics' Change in Acquisitions & Divestments rose 11544.92% to $150.8 million in Q2 2025 from the same period last year, while for Sep 2025 it was $544.3 million, marking a year-over-year increase of 7148.28%. This contributed to the annual value of $489.8 million for FY2024, which is 13531.19% up from last year.
  • Summit Therapeutics' Change in Acquisitions & Divestments amounted to $150.8 million in Q2 2025, which was up 11544.92% from $160.5 million recorded in Q1 2025.
  • In the past 5 years, Summit Therapeutics' Change in Acquisitions & Divestments ranged from a high of $233.0 million in Q4 2024 and a low of $38.2 million during Q2 2023
  • For the 3-year period, Summit Therapeutics' Change in Acquisitions & Divestments averaged around $112.1 million, with its median value being $109.4 million (2023).
  • Within the past 5 years, the most significant YoY rise in Summit Therapeutics' Change in Acquisitions & Divestments was 28465.88% (2024), while the steepest drop was 3237.47% (2024).
  • Over the past 3 years, Summit Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $60.6 million in 2023, then soared by 284.66% to $233.0 million in 2024, then plummeted by 35.27% to $150.8 million in 2025.
  • Its Change in Acquisitions & Divestments was $150.8 million in Q2 2025, compared to $160.5 million in Q1 2025 and $233.0 million in Q4 2024.